NYSE:ACH Accendra Health (ACH) Stock Price, News & Analysis $3.33 -0.14 (-4.03%) As of 10:39 AM Eastern Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Accendra Health Stock (NYSE:ACH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Accendra Health alerts:Sign Up Key Stats Today's Range$3.29▼$3.5150-Day Range$2.55▼$3.9352-Week Range$1.84▼$8.40Volume123,480 shsAverage Volume958,420 shsMarket Capitalization$255.01 millionP/E RatioN/ADividend YieldN/APrice Target$5.17Consensus RatingHold Company Overview Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions. Read More Accendra Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreACH MarketRank™: Accendra Health scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingAccendra Health has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAccendra Health has a consensus price target of $5.17, representing about 48.0% upside from its current price of $3.49.Amount of Analyst CoverageAccendra Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Accendra Health's stock forecast and price target. Earnings and Valuation2.1 / 5Proj. Earnings Growth54.84% Earnings GrowthEarnings for Accendra Health are expected to grow by 54.84% in the coming year, from $0.31 to $0.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accendra Health is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAccendra Health has a PEG Ratio of 5.35. PEG Ratios above 1 indicate that a company could be overvalued. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.83% of the float of Accendra Health has been sold short.Short Interest Ratio / Days to CoverAccendra Health has a short interest ratio ("days to cover") of 6.69.Change versus previous monthShort interest in Accendra Health has recently decreased by 11.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAccendra Health does not currently pay a dividend.Dividend GrowthAccendra Health does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest10 people have searched for ACH on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Accendra Health insiders have not sold or bought any company stock.Percentage Held by Insiders2.29% of the stock of Accendra Health is held by insiders.Percentage Held by InstitutionsAccendra Health has minimal institutional ownership at this time.Read more about Accendra Health's insider trading history. Receive ACH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accendra Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACH Stock News HeadlinesAccendra Health Announces Expiration and Final Results of Offers and Consent SolicitationsJune 23, 2026 | businesswire.comAccendra Health Announces Early Results of Offers and Consent SolicitationsJune 10, 2026 | businesswire.comNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried to acquire it outright for $40 billion - the White House blocked the deal on national security grounds. So NVIDIA settled for a 20-year supply deal instead. Its architecture delivers '2-3x performance per watt' by NVIDIA's own admission, and its data-center royalties more than doubled last quarter. Analyst Dylan Jovine - who called Palantir at $7.38 and Rocket Lab at $3.80 - has named it his number-one pick ahead of its July 29th earnings report.July 20 at 1:00 AM | Behind the Markets (Ad)Accendra Health Announces Offers and Consent SolicitationsMay 22, 2026 | businesswire.comAccendra Health Shareholders Approve Amended Omnibus Incentive PlanMay 15, 2026 | tipranks.comAccendra Health, Inc. (ACH) Shareholder/Analyst Call Prepared Remarks TranscriptMay 14, 2026 | seekingalpha.comAccendra Health, Inc. (NYSE:ACH) Q1 2026 Earnings Call TranscriptMay 12, 2026 | insidermonkey.comAccendra Health Makes Progress Addressing Its Debt LoadMay 11, 2026 | seekingalpha.comSee More Headlines ACH Stock Analysis - Frequently Asked Questions How have ACH shares performed this year? Accendra Health's stock was trading at $2.64 on April 9, 2026. Since then, ACH stock has increased by 32.2% and is now trading at $3.49. How were Accendra Health's earnings last quarter? Accendra Health, Inc. (NYSE:ACH) released its quarterly earnings data on Monday, May, 11th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. The firm had revenue of $627.78 million for the quarter. Accendra Health had a negative net margin of 39.84% and a negative trailing twelve-month return on equity of 13.18%. Who are Accendra Health's major shareholders? Accendra Health's top institutional shareholders include Williams & Novak LLC (0.05%). How do I buy shares of Accendra Health? Shares of ACH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/11/2026Today7/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ACH's financial health is in the Green zone, according to TradeSmith. ACH has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry WHOLESALE - MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES Sub-IndustryN/A Current SymbolNYSE:ACH CIK75252 Webwww.accendrahealth.com Phone(804) 277-4304Fax804-723-7100Employees6,500Year FoundedN/APrice Target and Rating Average Price Target for Accendra Health$5.17 High Price Target$6.00 Low Price Target$4.50 Potential Upside/Downside+55.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($14.05) Trailing P/E RatioN/A Forward P/E Ratio10.71 P/E Growth5.35Net Income-$1.10 billion Net Margins-39.84% Pretax Margin-4.15% Return on Equity-13.18% Return on Assets1.65% Debt Debt-to-Equity RatioN/A Current Ratio0.49 Quick Ratio0.43 Sales & Book Value Annual Sales$2.73 billion Price / Sales0.09 Cash Flow$3.65 per share Price / Cash Flow0.91 Book Value($5.96) per share Price / Book-0.56Miscellaneous Outstanding Shares76,580,000Free Float74,830,000Market Cap$254.25 million OptionableN/A Beta1.58 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:ACH) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe gold strategy buried in Trump's plans that insiders are already watchingNancy Pelosi's portfolio gained 71 percent in 2024 while the S&P 500 returned just 28 percent. In 2023, she ea...American Alternative | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredThe chipmaker 148 times smaller than NVIDIA supplying MuskAccording to Yahoo Finance, Elon Musk's latest project could 'upend another industry just as he did with cars ...Brownstone Research | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accendra Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Accendra Health With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
